Eli Lilly and Co.

Lilly settles Zyprexa marketing suit for $1.4 billion

January 15, 2009
J.K. Wall
Indianapolis-based Lilly pleaded guilty to one violation of the Food, Drug and Cosmetic Act on Thursday and agreed to pay $1.42 billion to settle both that criminal charge as well as civil lawsuits in which it did not admit wrongdoing.
More

Lilly eyes generic biotech drugsRestricted Content

January 5, 2009
Generic drugmakers have been the nemesis of companies like Eli Lilly and Co., but now the Indianapolis-based company and its peers want to get in the generic game themselves.
More

Lilly makes $6.5B acquisitionRestricted Content

December 29, 2008
J.K. Wall
Eli Lilly and Co. CEO John Lechleiter played a game of pharmaceutical poker with former Lilly Chief Financial Officer Jim Cornelius—and won.
More

Generic meds cost more than consumers realizeRestricted Content

December 15, 2008
Generic drug makers drive up the cost of name-brand drugs developed by locally based Eli Lilly and Co. and other pharmaceutical firms.
More

Lilly fighting with generic drug firms over Cymbalta, Alimta, 5 other medicationsRestricted Content

December 8, 2008
J.K. Wall
Eli Lilly & Co. has filed lawsuits against seven generic drug companies in federal court in Indianapolis, asking a judge to declare its Cymbalta patent valid and to tell the generic companies to back off.
More

Eli Lilly investing $100M in China, hoping to attract research partners

December 1, 2008
Brian Spegele
Hoping to increase sales in China's rapidly growing pharmaceutical market, Eli Lilly and Co. is charging ahead with plans to invest $100 million in venture capital in the region over the next several years.
More

Despite sour economy, retail developers press onRestricted Content

December 1, 2008
Greg AndrewsMore

Lilly buys ImClone as part of strategy to capitalize on cancer-drug marketRestricted Content

October 13, 2008
J.K. Wall

Eli Lilly and Co. has written a $6.5 billion IOU to acquire the cancer drugs of ImClone Systems Inc. Cancer drugs are now the best-selling class of drugs in the world and one of the fastest growing.


More

Lilly taps hedge fund to cut research costs for Alzheimer's drugsRestricted Content

August 11, 2008
J.K. Wall

Eli Lilly and Co.'s unorthodox efforts to develop new treatments for Alzheimer's disease--if successful--could usher in a new approach to drug development. The Indianapolis-based pharmaceutical company announced that a New York hedge fund, TPG-Axon Capital, will invest up to $325 million to help cover the exorbitant development costs of two experimental compounds to treat Alzheimer's disease.

More

Janitors want Lilly, WellPoint to push for better health benefitsRestricted Content

April 14, 2008
J.K. Wall
Service Employees International Union Local 3 is backing local janitors as they restart contract negotiations April 16 with five of the largest janitorial contractors in Indianapolis. SEIU now is taking direct aim at Lilly, health insurer WellPoint Inc. and even some local hospitals, hoping they will pressure the janitorial contractors to come to terms.
More

Lilly expects FDA approval of long-acting version of ZyprexaRestricted Content

February 4, 2008
J.K. Wall
Eli Lilly and Co. hopes to extend the life of its best-seller Zyprexa with a potentially lucrative, long-acting form of the antipsychotic drug. But first, the Indianapolis-based drugmaker must win over a panel of medical experts convened by the U.S. Food and Drug Administration on Feb. 6.
More

Taurel passes the batonRestricted Content

December 31, 2007
J.K. Wall
A new leader will guide the city's largest company in 2008, with some of the biggest challenges in its history on the horizon. Eli Lilly and Co. announced Dec. 18 that CEO Sidney Taurel will step down March 31 and will be replaced by President John C. Lechleiter, who has been the heir apparent for more than two years.
More

New Lilly CEO called analytical, 'incredibly warm'Restricted Content

December 24, 2007
J.K. Wall
John C. Lechleiter, whom Eli Lilly and Co.'s board voted to replace Sidney Taurel as CEO, is known for getting things done and yet also for being good at analysis and relating to people under him. Taurel will step down at the end of March but remain chairman until the end of 2008.
More

Taurel helped Lilly weather Prozac defeat, but he also stumbledRestricted Content

December 24, 2007
J.K. Wall
When Eli Lilly and Co. CEO Sidney Taurel announced his retirement Dec. 18, he said he was leaving the company in good shape. And he can cite plenty of evidence to support him. But when Taurel steps down as CEO March 31, he also will leave a legacy of a languishing stock price and some costly mistakes that some think could have been avoided. "The facts are the facts; I guess you can't ignore it. The stock price has been...
More

Lilly's plan to outsource more work is good news, bad newsRestricted Content

December 17, 2007
J.K. Wall
Eli Lilly and Co. will shrink itself with "great intensity" over the next few years, in part by outsourcing. For other local life sciences firms, that's a fat pitch for new business. But it's not clear if non-Lilly firms can grow fast enough to offset the jobs and wages Indianapolis will lose from Lilly.
More

Lilly under gun to replace aging blockbuster ZyprexaRestricted Content

November 5, 2007
J.K. Wall
There's a $2 billion hole in Eli Lilly and Co.'s future. That's roughly how much pretax profit Lilly derives each year from its best-seller, Zyprexa, according to calculations by IBJ. And it's how much black ink will start running off Lilly's books once Zyprexa's U.S. and European patents expire in 2011.
More

Taurel draws fire for getting rich while stock strugglesRestricted Content

May 28, 2007
J.K. Wall
Eli Lilly and Co. stock has returned just 1 percent per year in the nine years since CEO Sidney Taurel took office. Meanwhile, Taurel has taken home $44 million in pay and been given stock options valued at $114 million more. But most Lilly shareholders aren't raising a call for Taurel to hit the trail.
More

Lilly still breathing in inhaler pursuitRestricted Content

April 2, 2007
J.K. Wall
Pfizer Inc.'s new inhaled insulin product, Exubera, has stumbled out of the gate. That would appear to keep the door open for Eli Lilly and Co., as well as for other companies racing to develop inhaled insulin. But Pfizer's troubles might cause doctors and patients to sour on all inhaled insulin products.
More

Ariad patent victory over Lilly among largest in 2006

January 3, 2007
Eli Lilly and Co.’s loss in May of a patent-infringement lawsuit brought by Ariad Pharmaceuticals Inc. went down as the 6th-largest such jury award last year, a Bloomberg analysis shows.
More

Complaints accuse Lilly of illegally marketing ZyprexaRestricted Content

December 11, 2006
Tom Murphy
Eli Lilly and Co. is facing another round of litigation over its star seller, Zyprexa, as insurers and third-party payers ask to be reimbursed for covering the antipsychotic drug.
More

Lilly decides to self-insure for product liabilityRestricted Content

September 4, 2006
Tom Murphy
Eli Lilly and Co. has picked an insurer it knows extremely well to cover future problems in the high-stakes world of product liability litigation--itself. The Indianapolis drugmaker opted for self-insurance after struggling to find coverage in what it terms a "very restrictive insurance market."
More

Endowment's plan to diversify erodes one of Lilly's takeover safeguardsRestricted Content

July 31, 2006
Peter Schnitzler
The July 21 announcement by Lilly Endowment Inc. that it will reduce its holdings in Eli Lilly and Co. by $2 billion will have enormous repercussions. It's meant to decrease volatility in the endowment's assets, but it also erodes one of Lilly's key antitakeover provisions.
More
Page  << 21 22 23 pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. I keep wondering why I keep hearing about this problem of corporations leaving America, and I never hear a reasonable proposal to lower corporate tax rates and raise personal rates on income from capital gains and dividends, especially for high earners. It is just too simple of a solution for Congress to embrace?

  2. Are you financially down and you need money to settle your dept,or you need money to start up a business or to invest on a huge business,we also offer Loans to individuals, Firms and cooperate bodies at low interest rate , loan terms determinant,Loan amount between the sum of $5,000.00 to $100,000,000.00. US Dollars And Euro. Loan for developing businesses a competitive edge/ business expansion. We Offer The Following Kinds Of Loans. Personal Loans (Secure and Unsecured) Business Loans (Secure and Unsecured) Consolidation Loan FIRST INFORMATIONS NEEDED ARE: BORROWER’S DATA’S INFORMATION,FILL AND RETURN FOR QUICK START UP PROCESS. Name:_________ Last Name:_________ Age:_________ Contact Address:_________ Country:_________ Amount Needed as Loan:_________ Loan Duration:_________ Phone Number__________ Monthly Income/Yearly Income:_________ Purpose for Loan:_________ Occupation:_________ How Soon is Loan Needed__________ Email via: albertbrownfirm@outlook.com

  3. is a disaster. SR37 already needs to be built to interstate standards between 465 and SR144. Southport Road is a mess each morning and evening.

  4. Bass Pro Shops would be good for the mall as well as a Giant Eagle Market District or a Jungle Jim's International Market Place grocery store like the one near Cincinnati Ohio.A Disney quest indoor theme park would be good.An Academy outdoor store would be good too.Indoor Circus shows and magic shows would be good as well. A casino with sports bar would be good.A Disney theater inside that shows movies and Broadway shows would work.Nashville Tennessee concert shops with indoor neon lights would be good.How about a theater that shows travel shows and theme parks. A train store would be good.How about a giant toy store with high tech video games.

  5. This development is in addition to Allpoints Midwest 5, Aitrtek, a recent FedEx and more in Plainfield. Greenwood and Brownsburg also have similar projects.

ADVERTISEMENT